Literature DB >> 22496618

IκB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines.

Garima Jain1, Cornelia Voogdt, Anna Tobias, Klaus-Dieter Spindler, Peter Möller, Marcus V Cronauer, Ralf B Marienfeld.   

Abstract

Enhanced nuclear localization of nuclear factor κB (NF-κB) in prostate cancer (PCa) samples and constitutive NF-κB signaling in a class of PCa cell lines with low androgen receptor (AR) expression (PC3 and DU-145) imply an important role of the IκB kinase (IKK)/NF-κB system in PCa. However, most PCa and PCa cell lines depend on the activity of the AR, and the role of NF-κB in these AR-expressing PCa remains unclear. Here, we demonstrate that inhibition of NF-κB signaling by the IKK inhibitor BMS345541 reduced proliferation and increased apoptosis in AR-expressing PCa cell lines. Furthermore, AR activity and target gene expression were distinctively reduced, whereas AR protein levels remained unaltered on BMS345541 treatment. Similar effects were observed particularly after small interfering RNA (siRNA)-mediated knockdown of IKK1, but not by siRNA-mediated suppression of IKK2. Moreover, IKK1 overexpression augmented 5α-dihydrotestosterone-induced nuclear AR translocation, whereas nuclear AR was reduced by IKK1 knockdown or BMS345541. However, because IKK1 also enhances the activity of a chronically nuclear AR mutant, modulation of the subcellular distribution seems not to be the only mechanism by which IKK1 enhances AR activity. Finally, reduced in vivo AR phosphorylation after BMS345541 treatment and in vitro AR phosphorylation by IKK1 or IKK2 imply that AR constitutes a novel IKK target. Taken together, our data identify IKK1 as a potentially target structure for future therapeutic intervention in PCa.
Copyright © 2012 Neoplasia Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22496618      PMCID: PMC3323896          DOI: 10.1593/neo.111444

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  34 in total

1.  Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.

Authors:  X Y Zhao; P J Malloy; A V Krishnan; S Swami; N M Navone; D M Peehl; D Feldman
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

2.  BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice.

Authors:  James R Burke; Mark A Pattoli; Kurt R Gregor; Patrick J Brassil; John F MacMaster; Kim W McIntyre; Xiaoxia Yang; Violetta S Iotzova; Wendy Clarke; Joann Strnad; Yuping Qiu; F Christopher Zusi
Journal:  J Biol Chem       Date:  2002-10-25       Impact factor: 5.157

Review 3.  Androgen receptor phosphorylation.

Authors:  L J Blok; P E de Ruiter; A O Brinkmann
Journal:  Endocr Res       Date:  1996-08       Impact factor: 1.720

4.  Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites.

Authors:  Daniel Gioeli; Scott B Ficarro; Jesse J Kwiek; David Aaronson; Mathew Hancock; Andrew D Catling; Forest M White; Robert E Christian; Robert E Settlage; Jeffrey Shabanowitz; Donald F Hunt; Michael J Weber
Journal:  J Biol Chem       Date:  2002-05-15       Impact factor: 5.157

5.  Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer.

Authors:  Vincent Fradet; Laurent Lessard; Louis R Bégin; Pierre Karakiewicz; Anne-Marie Mes Masson; Fred Saad
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

6.  Characterization of the Ikappa B-kinase NEMO binding domain.

Authors:  Michael J May; Ralf B Marienfeld; Sankar Ghosh
Journal:  J Biol Chem       Date:  2002-09-19       Impact factor: 5.157

7.  Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate.

Authors:  Christopher Sweeney; Lang Li; Rajasubramaniam Shanmugam; Poornima Bhat-Nakshatri; Vetrichelvan Jayaprakasan; Lee Ann Baldridge; Thomas Gardner; Martin Smith; Harikrishna Nakshatri; Liang Cheng
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

8.  Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence.

Authors:  Jeffrey S Ross; Bhaskar V S Kallakury; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Bradley Stringer
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

9.  Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells.

Authors:  Junghan Suh; Faribourz Payvandi; Leonard C Edelstein; Peter S Amenta; Wei-Xing Zong; Céline Gélinas; Arnold B Rabson
Journal:  Prostate       Date:  2002-08-01       Impact factor: 4.104

10.  The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells.

Authors:  Alexander V Gasparian; Ya Juan Yao; Dariusz Kowalczyk; Ludmila A Lyakh; Apollon Karseladze; Thomas J Slaga; Irina V Budunova
Journal:  J Cell Sci       Date:  2002-01-01       Impact factor: 5.285

View more
  17 in total

1.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

2.  Cytoplasmic TRADD confers a worse prognosis in glioblastoma.

Authors:  Sharmistha Chakraborty; Li Li; Hao Tang; Yang Xie; Vineshkumar Thidil Puliyappadamba; Jack Raisanen; Sandeep Burma; David A Boothman; Brent Cochran; Julian Wu; Amyn A Habib
Journal:  Neoplasia       Date:  2013-08       Impact factor: 5.715

3.  Kinase modulation of androgen receptor signaling: implications for prostate cancer.

Authors:  Kalpit Shah; Neil A Bradbury
Journal:  Cancer Cell Microenviron       Date:  2015-11-19

4.  Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα.

Authors:  Subrata Manna; Bipradeb Singha; Sai Aung Phyo; Himavanth Reddy Gatla; Tzu-Pei Chang; Shannon Sanacora; Sitharam Ramaswami; Ivana Vancurova
Journal:  J Immunol       Date:  2013-07-26       Impact factor: 5.422

5.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

6.  Phospho Tensin Homolog in Human and Lipid Peroxides in Peripheral Blood Mononuclear Cells Following Exposure to Flavonoids.

Authors:  William Y Boadi; Elbert L Myles; Alekzander S Garcia
Journal:  J Am Coll Nutr       Date:  2019-06-13       Impact factor: 3.571

7.  The IκB kinase complex is required for plexin-B-mediated activation of RhoA.

Authors:  Matthias Zielonka; Ramesh K Krishnan; Jakub M Swiercz; Stefan Offermanns
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

8.  Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.

Authors:  Kiera Rycaj; Eun Jeong Cho; Xin Liu; Hsueh-Ping Chao; Bigang Liu; Qiuhui Li; Ashwini K Devkota; Dingxiao Zhang; Xin Chen; John Moore; Kevin N Dalby; Dean G Tang
Journal:  Oncotarget       Date:  2016-03-22

9.  Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.

Authors:  Henrique B da Silva; Eduardo P Amaral; Eduardo L Nolasco; Nathalia C de Victo; Rodrigo Atique; Carina C Jank; Valesca Anschau; Luiz F Zerbini; Ricardo G Correa
Journal:  Prostate Cancer       Date:  2013-04-29

10.  Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells.

Authors:  Friedemann Zengerling; Wolfgang Streicher; Andres J Schrader; Mark Schrader; Bianca Nitzsche; Marcus V Cronauer; Michael Höpfner
Journal:  Int J Mol Sci       Date:  2012-09-14       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.